Symmetry and complexity in protein oligomers  by Gross, Michael
Magazine
R175Feature
Symmetry and complexity in protein oligomers
Molecular machines like the chaperonins and the proteasome are intriguingly 
complex but also beautifully symmetrical. Recent research suggests how they 
evolved and adds to our understanding of their function. Michael Gross reports.All proteins lack mirror symmetry by 
default, as they are built from chiral 
amino acids. However, the majority 
of proteins occur in the shape of 
oligomeric complexes, and within these 
assemblies one often finds a rotational 
symmetry, meaning that rotating the 
complex by 360 degrees/n, with n being 
an integer, will produce an identical 
structure. This kind of symmetry occurs 
in a wide variety of protein oligomers, 
ranging from the simple dimers with 
a yin-yang-style twofold rotational 
symmetry to the icosahedral 
symmetries of many viral capsids. 
A few years ago, work from the group 
of David Baker at the University of 
Washington in Seattle provided some 
insights into the evolution of these 
complex symmetrical shapes, as 
summarised in a dispatch in this journal 
(Curr. Biol. (2008), 19, R25–R26). The group 
suggested that rotationally symmetrical 
complexes are so widespread due 
to statistical reasons rather than a 
direct evolutionary benefit of having a 
symmetrically built protein complex. 
In a symmetrical dimer, any stabilising 
interaction between residue A of one 
subunit and residue B of another will 
inevitably occur twice, because residue 
B of the first mentioned molecule will 
similarly interact with residue A of the 
second. Using molecular modelling to 
study the molecular interactions within 
existing and theoretically possible 
dimers, Baker and co-workers found 
that the symmetrical complexes, 
though relatively rare in the structural 
space of all conceivable assemblies, 
are strongly overrepresented in the 
subset of energetically favourable 
oligomers. Therefore, they are much 
easier for evolution to discover than 
unsymmetrical complexes. 
Evolving complexity
If evolution is most likely to come up 
with symmetrical oligomers made 
of identical subunits, how did the 
assemblies arise that have a complex 
mixture of subunits, such as the 
proteasome? Joseph W. Thornton and 
colleagues at the University of Oregon at Eugene have recently shown how 
identical subunits in a ring complex 
can become different subunits in very 
simple and plausible steps. 
They studied the hexameric 
transmembrane pore of the eukaryotic 
V-ATPase, known as the V0 ring. In 
most eukaryotes, the ring consists 
of five identical subunits known as 
Vma3, plus a single copy of the related 
protein Vma16. In fungi, however, 
the Vma3 subunit that is located 
clockwise (as seen from the outside of 
the membrane) adjacent to Vma16 is 
replaced by another variant known as 
Vma11, a diverged duplicate of Vma3. 
Using phylogenetic methods, 
Thornton and colleagues extrapolated 
the most likely amino acid sequences 
of the ancestral Vma3 and Vma11 
subunits from the common ancestor of 
all fungi, as well as the pre-duplication 
ancestral protein from which both 
evolved. They then reconstructed the 
genes for these putative ancestral 
sequences. Expressing the ring 
proteins in yeast strains in which the modern proteins were knocked out, the 
researchers found that the common 
ancestor of Vma3 and Vma11, which 
they called Vma3-11, can replace either 
or both of its modern-day descendants 
to restore viability (Nature (2012), 
481, 360–364). This shows there is 
no intrinsic superiority to the three-
component system that would explain 
its evolutionary success. 
According to the research, the origin 
of the more complex system is likely 
to have been purely accidental. The 
gene of the common ancestor Vma3-11 
duplicated, and then, as the authors 
show experimentally, a single loss-of-
function mutation in each version is 
sufficient to make both versions lose the 
ability to form the ancestral 5+1 version 
of the ring. Using fusion proteins, the 
researchers showed that Vma11 lost 
the ability to bind its own kind on the 
left (anti-clockwise) flank, but retained 
the ability to bind its now genetically 
separated twin on the right, while fungal 
Vma3 lost the ability to bind Vma16 on 
the left, but retained the interactions 
with its own kind and with a Vma16 
subunit on the right. In comparison 
to the common ancestor Vma3-11 
and to non-fungal Vma3, which can Strong symmetry: Barrel-shaped protein complexes with six, seven, or eightfold rotational 
symmetry are quite common in nature. Some, like GroEL, retain perfect symmetry, while others, 
like the proteasome, develop differences between the subunits. The photo shows Castel del 
Monte, a striking example of protein-like architecture with eightfold symmetry, built in the Apulia 
region of southeast Italy more than 700 years before the first protein structures were solved. 
(Photo: © Tips Images/Tips Italia Srl a socio unico/Alamy.)
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constitutive version of the proteasome found in most mammalian cells. (Photo: © Prof. Michael 
Groll/Technische Universitaet Muenchen.)both bind their own kind and Vma16 
on either side, this set of restrictions 
represents a significant loss of function 
in the descendants. The problem can 
be solved by only one arrangement of 
subunits, namely by having exactly one 
Vma11 subunit at the anti-clockwise 
end of the chain of Vma3 subunits. 
Thus, in this instance, the increase 
in complexity and loss of symmetry 
does not require one of those relatively 
rare mutations that spontaneously 
provides additional functionality. Two 
complementary and much more 
likely loss-of-function mutations are 
sufficient to explain the evolutionary 
change that happened around the 
time when the fungi separated from 
other eukaryotic lineages. 
“By using reconstructed ancestral 
genes, we were able to trace the genetic 
and functional mechanisms by which 
complexity increased in the ring,” 
Thornton summarises. “Simple 
degenerative processes are sufficient to account for the incorporation of a new 
subunit as an obligate component of the 
more complex fungal ring. All it took was 
the selective and asymmetrical loss of  
interfaces — there’s no evidence that any 
of the components of the system, or the 
system itself, evolved any new functions 
during the increase in complexity.”
Ford Doolittle wrote in an 
accompanying commentary that this 
study provided the most compelling 
evidence to date for the theory known 
as constructive neutral evolution, which 
explains how neutral processes may 
end up producing higher complexity. 
However, he also cautioned that “one 
can never prove that some subtle, 
unidentified selective advantage was 
not involved in the evolution of the V-
ATPase protein ring.”
Proteasome patchwork
One medically relevant example of ring 
complexes that diversified from highly 
symmetrical to complex structures is the proteasome, which plays important 
roles in intracellular protein degradation 
and in the presentation of peptide 
antigens by the immune system. All 
proteasomes consist of a core particle 
made of four rings with seven subunits 
each and flanked by regulatory 
particles. Within the core particle, the 
two inner rings are made of catalytic 
subunits harbouring the proteolytic 
function, while the outer rings gate the 
access of substrate proteins to these 
proteolytic sites. Intriguingly, the core 
proteasomes of archaea only have two 
kinds of subunits, a catalytic one (b) that 
accounts for the entire 14 units of the 
two inner rings, and a structural one (a) 
that builds the two outer rings. Thus, 
the entire core archaeal proteasome 
complex maintains the seven-fold 
rotational symmetry that is also found in 
the bacterial chaperonin GroEL. 
By contrast, eukaryotes typically 
have several different kinds of subunits 
in each ring of their core proteasomes, 
and there seems to be a trend that 
the complexity of the proteasome 
increases with the complexity of the 
host organism. In yeast, one finds 
seven different subunits in the inner 
ring, labelled b1 to b7. In contrast to the 
neutral evolution of complex oligomers 
discussed above, the diversity of 
the b subunits has a clear functional 
advantage in this context, as they have 
different binding pockets and thus 
different substrate specificities. 
In mammals, the diversification has 
gone one step further and resulted in 
different proteasome particles being 
specialised for different tasks. In addition 
to the core proteasome constitutively 
expressed in most cell types (cCP), 
certain cells of the immune system have 
a different kind of proteasome, known 
as the immunoproteasome (iCP), built 
from different types of subunits labelled 
with the letter ‘i’, e.g. b5i. The main task 
of this variant is to produce peptides 
for the MHC I complex to present on 
the cell surface. A third version of the 
proteasome, tCP, is found in cortical 
thymic epithelial cells and has the 
variant subunit b5t. 
The immunoproteasome plays an 
important role in autoimmune diseases 
such as multiple sclerosis, rheumatism, 
and type I diabetes. Medical researchers 
hope that inhibitors that specifically 
target the variant subunits, such as 
b5i, which is believed to play a role in 
cytokine production, could become 
useful drugs against such diseases and 
against inflammatory disorders. 
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Michael Groll at the Technical University 
of Munich and of Marcus Groettrup at 
the University of Konstanz have recently 
solved the crystal structures of both the  
constitutive proteasome and the 
immunoproteasome of mice, each with 
and without the epoxyketone PR957, 
which is the only selective inhibitor 
of b5i known so far. In addition, the 
researchers also solved the structure of 
the yeast proteasome with and without 
this inhibitor (Cell (2012), 148, 727–738). 
The detailed analysis of these 
structures revealed the molecular 
basis for the specificity of the inhibitor, 
which turned out to be extremely 
subtle. The researchers found that 
a single methionine residue in the 
immunoproteasome adopts a different 
conformation than in the constitutive 
proteasome due to small structural 
differences in its surroundings. “This 
distinct conformation is crucial,” 
explains the first author of the paper, Eva 
Maria Huber. “It results in a larger pocket 
in the immunoproteasome, which 
therefore preferentially accommodates 
bulky amino acids and also the inhibitor. 
In contrast, constitutive proteasomes 
harbor a significantly smaller cavity that 
hampers binding of PR-957.”
What does all this mean for disease 
and drug development? “How the 
immunoproteasome is mechanistically 
involved in the pathogenesis of 
autoimmune diseases is still elusive,” 
says Marcus Groettrup. “The 
proteasome can perform site-specific 
cleavages within proteins and release 
a processed, biologically active 
polypeptide. We hypothesize that the 
immunoproteasome may selectively 
process or degrade a factor which is 
required for proinflammatory immune 
responses in autoimmunity.”
As yet, only one approved 
pharmaceutical agent, the cancer drug 
bortezomib, targets the proteasome, but 
the authors hope that, on the basis of the 
detailed structural knowledge they have 
provided for the whole range of different 
subunits in the constitutive proteasome 
and in the immunoproteasome, more 
specific drugs can be developed 
to target specific functions of the 
proteasome. Thus, understanding  
the complexities of oligomeric  
proteins will also become very useful 
knowledge. 
Michael Gross is a science writer based at 
Oxford. He can be contacted via his web page 
at www.michaelgross.co.ukPieter Roelfsema
Pieter Roelfsema studied medicine 
in Groningen, Netherlands between 
1983 and 1991. He worked for his 
PhD degree in Frankfurt, Germany 
between 1991 and 1995 in the lab 
of Wolf Singer, where he studied the 
role of neuronal synchrony in feature 
binding. He received his PhD from 
the University of Amsterdam in 1995 
and came back to the Netherlands to 
do a post-doc studying the neuronal 
mechanisms for perceptual grouping 
in the primate visual system. Since 
2007 he has been the director 
of the Netherlands Institute for 
Neuroscience (KNAW) in Amsterdam 
and he is also strategic professor at 
the VU University in Amsterdam. If 
asked what summarizes his approach 
to science he says ‘usually too 
ambitious but sometimes it comes 
together’.
Why did you go into neuroscience? 
At high school I was first attracted to 
the physical sciences. But I changed 
my mind because a life surrounded 
by people seemed more interesting 
than one surrounded by test tubes. 
So I decided to study medicine so 
that I could learn about the science 
with the prospect of helping patients. 
The first two years of study, which I 
did in Groningen, in the north of the 
Netherlands, were very interesting. 
From the third year on we learned 
the mappings between symptoms 
and diseases. I vividly remember 
my father giving me the book 
‘Gödel Escher Bach’ by Douglas 
Hofstadter. It completely changed my 
perspective. From then on I wanted 
to know what consciousness is, how 
we think and remember. I started 
to read textbooks on neuroscience 
and then papers. I was fascinated 
by papers I read on learning and 
plasticity by Yves Fregnac, Mark Bear 
and Wolf Singer and I interrupted my 
medical training to do a student’s 
project on the neurophysiology of 
snails and then one on learning in 
rats. I learned a lot in this period, but 
also came to realize that doing good 
research is team work. As a novice 
it seemed to be a good idea to go to 
a top-level lab. Fernando Lopes da 
Silva helped me by sending a letter 
Q & A of recommendation to Wolf Singer at the Max-Planck-Institute in Frankfurt. 
When I went to Frankfurt for an 
interview, Singer told me that I should 
first finish training for my MD degree, 
but that I would be welcome in his 
lab afterwards. So I went back to 
Groningen for two years and finished 
my clinical training. I was relieved to 
find out that Singer’s offer to join his 
lab was still valid after these years.
Why did you choose to study 
‘binding’ in visual perception? It was 
not my own choice. I was attracted to 
Wolf Singer’s lab to study plasticity, 
but the binding problem — how the 
brain binds together information 
about the various features of a 
particular object which may be 
processed in separate areas — and 
the role of oscillatory synchrony 
had become the major research 
topic in his lab when I arrived. The 
scientific climate in the Singer lab 
was fantastic, with Andreas Engel, 
Peter König, and later Pascal Fries 
and many others present. People 
were excited about the binding 
problem and we all felt that we were 
in the middle of a great discovery. For 
my first project, I recorded from the 
visual cortex of cats with amblyopia. 
I was thrilled to record from single 
neurons that we stimulated with a 
bar of light using a hand-held lamp, 
very much as Hubel and Wiesel had 
done. In my project, we found that 
cortical neurons connected to the 
amblyopic eye did not synchronize 
as well as those connected to the 
normal eye, supporting the idea of 
a functional role of synchrony in 
cortical processing. Later projects 
focused on the interactions between 
brain areas where we also observed 
synchronization. We did realize, 
however, that one crucial piece of 
evidence for binding-by-synchrony 
was lacking: no one had shown that 
the patterns of synchrony in the 
visual cortex were correlated with 
binding in perception. 
What has been your biggest 
research mistake? I am not sure 
that I would call it a mistake, but the 
concept of binding-by-synchrony 
turned out to be wrong. When I 
went back to Amsterdam in 1995 
to work with Henk Spekreijse and 
Victor Lamme, I was determined to 
show once and for all that synchrony 
was responsible for binding in 
